来源：新华网 全球癌症数据库数据显示，2022年全球口腔癌死亡人数约为18.8万。 据公报介绍，在健康口腔中，通常检测不到提示淋巴管内皮细胞分裂的相关标志蛋白。研究人员指出， 在诊断阶段尽早识别侵袭性癌症很重要，从而仍可通过治疗措施降低复发和死亡风险。目前，早期口腔 癌治疗主要依赖手术，但对于是否以及如何精准选择辅助治疗仍缺乏可靠手段，发现新的标志物一方面 可以让高风险患者接受更有效治疗，另一方面可避免预后较好患者承受不必要的辅助治疗可能带来的严 重不良反应。 相关研究论文已发表在美国《细胞报告·医学》杂志上。研究人员表示，这一研究成果有望进一步发展 为临床检测工具。下一步，他们计划研究相关蛋白标志物在其他类型癌症中是否具有类似预测价值。 新华社赫尔辛基2月23日电（记者朱昊晨 徐谦）芬兰图尔库大学团队开展的一项新研究发现，淋巴管系 统的特定变化，可在早期帮助医生识别侵袭性强、复发风险高的口腔癌。 图尔库大学近日发布公报说，该校研究人员通过分析约300名芬兰早期口腔癌患者样本发现，肿瘤组织 的淋巴管内皮细胞中出现与细胞分裂有关的蛋白质信号。分析还显示，在部分癌症患者样本中，处于分 裂状态的淋巴管内皮细胞数量较 ...

这一研究纳入了27例停药后病情仍然保持稳定的iMCD-TAFRO患者，在中位31个月的随访期间，23例 患者病情持续稳定，其中20例患者病情完全缓解。预计在停药后6个月、1年和3年时，病情保持稳定的 比例分别为96.3%、85.2%和85.2%。 研究显示，部分iMCD-TAFRO患者并不需要"无限期"治疗，或可达到治愈。临床操作中，对于达到生化 完全缓解的iMCD-TAFRO患者，尝试停药成为一个值得考虑的临床选项。 来源：新华社 近日，《美国血液学杂志》发表了北京协和医院血液内科团队和浙江大学医学院附属第一医院血液科团 队合作的多中心研究成果，研究显示，对于特发性多中心型卡斯尔门氏病（Castleman disease）中最严 重的临床亚型iMCD-TAFRO患者，在治疗后达到缓解的情况下，部分患者无需长期维持治疗。 卡斯尔门氏病是一种血液系统罕见疾病，被纳入我国《第一批罕见病目录》。其中iMCD-TAFRO亚型 以细胞因子风暴为突出表现，严重威胁患者脏器功能和生命。 ...

针对健康寿命下滑及相关问题，韩国政府表示，将在相关计划中把"延长健康寿命、提升健康公平性"作 为核心目标，通过控制烟酒、增加民众体育活动等一系列政策改善国民健康。 新冠疫情也是导致健康预期寿命下降的原因之一。疫情期间，居家办公普及导致民众日常体育活动减 少，肥胖率和慢性疾病风险上升，对健康预期寿命产生负面影响；同时，新冠后遗症及相关健康损伤也 在一定程度上拉低了这一指标。 值得关注的是，韩国健康寿命的贫富差距仍在扩大。数据显示，2022年韩国收入前20%群体的健康预期 寿命为72.7岁，而收入后 20% 群体仅为64.3岁，二者差距达8.4岁，远高于 2012 年的6.7岁。专家分析认 为，收入越低的群体，暴露于吸烟、酗酒、慢性疾病等健康风险中的概率就越高，同时，他们在医疗资 源可及性、健康管理投入等方面也处于劣势，这一现状进一步加剧了韩国的健康不平等现象。 【环球时报驻韩国特约记者 黎枳银】综合韩联社、《朝鲜日报》《东亚日报》等媒体9日报道，韩国衡 量国民生命质量的综合性指标"健康预期寿命"时隔近十年再次跌破70岁关口，引发韩国社会对慢性疾病 管理及健康不平等问题的广泛关注。 据报道，韩国健康增进开发院发布 ...

中新网北京2月4日电 (记者 孙自法)施普林格·自然旗下专业学术期刊《自然-医学》最新发表一篇癌症研 究论文称，一项涵盖185个国家、36种癌症类型的分析显示，2022年全球近40%的新增癌症病例可能与 可改变的风险因素相关。 在本项研究中，IARC/WHO研究团队估计了全球及各国可能归因于30项可改变风险因素的癌症负担， 结合2022年的发病数据(来自185个国家的36种癌症类型)与约10年前的暴露流行情况，并在考虑风险因 素之间可能共存的前提下，计算了各风险因素与病例数量的关联。 他们指出，2022年全球1870万例新增癌症病例中，约有710万例(37.8%)能归因于这些可改变风险因素， 其中，吸烟(15.1%)、感染(10.2%)与饮酒(3.2%)是主要贡献因素，而肺癌、胃癌与宫颈癌合计约占这些 潜在可预防病例的近一半。 对于全球女性而言，人类乳头瘤病毒(HPV)或幽门螺杆菌等感染似乎是最大的癌症风险因素，与11.5% 的病例相关；而对于全球男性而言，最大风险因素是吸烟，与23.1%的病例相关。研究团队同时指出了 若干地域差异，例如撒哈拉以南非洲女性的癌症负担中，与可改变风险因素相关的比例最高(38.2 ...

尼帕病毒"人传人"依然是极小概率事件。 近期在印度发生的尼帕病毒病疫情会否出现流行病学中典型的"溢出事件"，发生较大规模的跨区域传播 和人际感染，受到东亚和东南亚地区国家的持续关注。 王林发表示，直至现在，对表现为脑炎的病例进行诊断也存在挑战。因为绝大多数脑炎患者与尼帕病毒 无关。此外，尼帕病毒感染既可表现为呼吸道症状，也可出现神经系统症状，且难以与其他感染性疾病 区分。基于此，在任何急诊医疗机构中，快速PCR检测或抗原检测都是关键诊断手段。 对此，杜克-新加坡国立大学医学院新兴传染病项目教授、新加坡流行病准备与应对研究项目 （PREPARE）首任执行主任王林发近日在接受第一财经专访时作出研判：总体来看，尼帕病毒在区域 或全球范围内的扩散风险"都非常低"，此次印度疫情大概率也不例外。 新加坡是最初发现尼帕病毒的国家之一。1998年前后，尼帕病毒在马来西亚的养猪场中被首次发现，随 后在马来西亚和新加坡的猪群和人群中暴发疫情。自该病毒在该国检出以来，新加坡始终对尼帕病毒病 保持密切监测和关注。目前，包括中国、新加坡在内的亚太多国均已发声称，正在密切关注印度西孟加 拉邦的尼帕病毒传播情况，并已经加强风险评估和疫情应 ...

Core Insights - An AI model named SleepFM has been developed by researchers at Stanford University to predict the risk of approximately 130 diseases based on a single night's sleep data, including heart disease, dementia, and certain cancers [1][2] - The model was trained using data from 65,000 participants, totaling nearly 600,000 hours of polysomnography data, marking the first use of AI to analyze such a large dataset of sleep information [1] Group 1 - The SleepFM model utilizes polysomnography, which records various physiological signals related to sleep, making it the "gold standard" for sleep assessment [1] - The training data includes records from 35,000 individuals at the Stanford Sleep Center, who have had their sleep and health monitored over 25 years [2] - The model has shown exceptional predictive capabilities for diseases such as Parkinson's, dementia, developmental delays, and cardiovascular diseases, with high accuracy in predicting prostate, breast, and skin cancers [2] Group 2 - Previous research on sleep and disease often focused on single indicators and specific diseases, neglecting the complexity of sleep physiology [2] - The new findings indicate that AI models can understand the "language" of sleep data, enabling flexible and efficient disease prediction [2]

Core Insights - The Suzhou Northern People's Hospital Clinical Pharmacology Research Center successfully passed the professional filing inspection for its bioequivalence testing specialty, marking a significant advancement in the hospital's clinical trial capabilities and contributing to the high-quality development of regional drug clinical trials [1][2]. Group 1: Inspection and Achievements - The Clinical Pharmacology Research Center underwent its first on-site inspection by experts from the Jiangsu Provincial Drug Supervision Administration on November 11-12, 2025, demonstrating thorough preparation by the research team led by Professor Shu Yusheng [1]. - The center currently has 28 drug clinical trial specialties and 41 medical device clinical trial specialties, capable of undertaking various clinical trial projects [1]. Group 2: Future Plans and Development - Following the successful filing of the bioequivalence testing specialty, the center aims to enhance its clinical trial quality management system and promote standardized processes, thereby elevating the hospital's research and clinical trial standards [2]. - Since its establishment in December 2023, the center has adhered to national regulations and quality management standards, with a facility covering approximately 3,600 square meters, equipped with 72 beds and 2 emergency beds [2]. - The center's research team consists of 16 staff members, including 10 with senior titles and 2 with intermediate titles, and features members from national and provincial drug clinical trial expert databases [2]. Group 3: Next Steps - The center plans to actively advance the filing application for its Phase I drug clinical trial specialty, aiming to undertake more high-quality innovative drug Phase I clinical trial projects [3].

Core Insights - The exploration of clinical applications related to brain-computer interfaces (BCI) is gaining traction in multiple hospitals across the country, with neurorehabilitation being a prominent area of focus [1] - A recent randomized controlled clinical study from Sun Yat-sen University Third Hospital provides preliminary evidence that BCI significantly enhances rehabilitation outcomes compared to traditional methods [3] Group 1: Clinical Research Findings - The study published in the prestigious journal Annals of Neurology confirms that BCI-controlled exoskeleton training significantly improves lower limb motor abilities and depressive symptoms in patients with spinal cord injury (SCI) [3] - The research systematically evaluates the dual role of BCI-controlled lower limb exoskeleton training in motor function recovery and cortical plasticity reconstruction for SCI patients [3] - Initial results indicate that SCI patients, even in early recovery stages, exhibit good neural interface adaptability, with BCI control accuracy reaching 95.2% and response times as short as 1.15 seconds, comparable to healthy controls [3] Group 2: Intervention Outcomes - After a 4-week intervention, the BCI-controlled exoskeleton training group (B+E) showed significantly better outcomes in key functional indicators such as lower extremity muscle strength (LEMS), walking speed (10MWT), walking endurance (6MWT), and depression scores (HADS-D) compared to the exoskeleton-only group (E) [5] - Electrophysiological analysis revealed significant enhancements in event-related desynchronization (ERD) in the μ/β band within the midline motor cortex region (FCz-Cz-CPz) for the B+E group, indicating structural remodeling of cortical networks [6] Group 3: Mechanism of Action - Unlike traditional passive training, the BCI system establishes a closed-loop pathway through real-time decoding of movement intentions and driving gait execution, significantly enhancing patients' subjective sense of participation in gait control [9] - This study provides the first evidence supporting the efficacy of BCI-controlled exoskeleton training over traditional methods in improving motor and emotional disorders in SCI patients, proposing a novel rehabilitation strategy centered on "brain-controlled driving and neural remodeling" [9] Group 4: Research Collaboration and Funding - The research was led by a team from Sun Yat-sen University Third Hospital in collaboration with Xi'an Jiaotong University, with multiple authors contributing to the study [10] - The study received funding from the National Natural Science Foundation and key research and development projects in Guangzhou [10]

Group 1 - The core point of the article is that Suzhou Ice Crystal Intelligent Medical Technology Co., Ltd. has recently completed a Series A financing round, raising tens of millions of RMB, with participation from investment institutions that achieved excellent results in the Sichuan centralized procurement [1] - Suzhou Ice Crystal Intelligent Medical Technology Co., Ltd. was established in 2021 and is located in Suzhou, focusing on research and experimental development [1] - The company has a registered capital of approximately 6.87 million RMB and has completed its Series A financing by 2026, with the transaction amount being tens of millions of RMB [1] Group 2 - The company has made investments in 7 other enterprises and holds 12 trademark registrations and 24 patents, along with 18 administrative licenses [1] - The shareholders of Suzhou Ice Crystal Intelligent Medical Technology Co., Ltd. include Zhang Jihong and several limited partnership investment firms [1]

Core Insights - A research team in Beijing has successfully created the world's first brain map specifically for the Chinese population, establishing normal reference values for 228 core brain structures, which can significantly enhance the diagnostic accuracy for neurodegenerative diseases like Alzheimer's and Parkinson's [1][2] Group 1: Research and Development - The study was a collaboration between Beijing Tiantan Hospital and Beijing Normal University, involving 105 research centers across the country, collecting nearly 28,000 high-quality MRI data samples, including over 24,000 from healthy individuals and more than 3,900 from patients with brain diseases [1] - The findings were published in the international journal Nature Neuroscience and have entered the clinical pilot phase [1] Group 2: Clinical Application - The brain map allows for precise reflection of the developmental, mature, and aging changes in the brains of the Chinese population, addressing the limitations of using Western population data which may lead to diagnostic biases [1][2] - An individualized brain health assessment system based on this research has been piloted at Tiantan Hospital, serving over 1,000 patients, and is capable of evaluating cognitive and motor functions, predicting drug and surgical efficacy, and warning of disability progression risks [2] Group 3: Future Directions - Future plans include integrating multimodal imaging, blood biomarkers, and genetic data to develop a comprehensive multimodal brain atlas system for the Chinese population, further advancing the precision diagnosis and treatment of major brain diseases [2] - The research has been patented and partnerships with several medical imaging companies have been established for clinical applications in brain health assessment and disease diagnosis [2]